Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial.

ABSTRACT: To examine whether treatment with epigallocatechin gallate (EGCG) influences progression of brain atrophy, reduces clinical and further radiologic disease activity markers, and is safe in patients with progressive multiple sclerosis (PMS). We enrolled 61 patients with primary or secondary PMS in a randomized double-blind, parallel-group, phase II trial on oral EGCG (up to 1,200 mg daily) or placebo for 36 months with an optional open-label EGCG treatment extension (OE) of 12-month duration. The primary end point was the rate of brain atrophy, quantified as brain parenchymal fraction (BPF). The secondary end points were radiologic and clinical disease parameters and safety assessments. In our cohort, 30 patients were randomized to EGCG treatment and 31 to placebo. Thirty-eight patients (19

SUBMITTER: Rust R 

PROVIDER: S-EPMC7954462 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature